Pharmaceuticals

A landmark bill in Congress and nationwide walks aim to channel millions into R&D for a genetic disorder affecting 500,000 Americans, creating a new roadmap for a cure.

A breakthrough drug for a rare disease gets a key nod, but its high price tag forces a showdown between patient need and Canada's public purse.

Cipla and Qilu are teaming up to launch a biosimilar for Keytruda, the world's top cancer drug, signaling a major shift in patient access and market dynamics.

A deep dive into PRF Technologies' audacious dual-engine strategy, as it simultaneously pushes for FDA trials and commercializes AI for the green energy grid.

As Claris Bio courts investors, it's not just capital on the line. At stake is a first-of-its-kind eye drop for a rare, blinding disease.

With a new cancer drug showing promise but cash reserves dwindling, Citius Pharma's CEO faces a critical test: convincing investors the pipeline is worth the risk.

The prestigious Prix Galien awards debut in Seoul, cementing South Korea's status as a life sciences leader and spotlighting a wave of homegrown innovation.

With Hepatitis C royalties declining, Enanta Pharmaceuticals faces investors this month to sell its vision: a future built on novel RSV and immunology drugs.

An estimated 13 million Americans live with Dupuytren's contracture, a progressive hand condition. A new campaign using mixed reality aims to change that.

Telehealth firm NexLife is disrupting the GLP-1 market with flat-rate pricing and novel sublingual options, a strategy aimed at accessibility amid regulatory scrutiny.

UCB's landmark agreement with the U.S. government trades pricing concessions for tariff exemptions, signaling a major shift in industry strategy.

A strategic merger combines Chemomab's promising drug, nebokitug, with Scipher's AI platform, aiming to de-risk development and transform RA treatment.

XYRA's new trial uses data from wearables to personalize doses of Budiodarone, a safer alternative to today's standard AF drugs. Is this the future?

After a strategic reset, Australian biopharma Immuron reports record sales and a stronger cash position, pivoting to partner its high-value drug candidates.

Samsung Biologics is raising KRW 3 trillion to buy a peptide specialist and build a mega-campus. It's a bold play that trades short-term dilution for long-term dominance.

GRI Bio showcases its promising IPF drug, GRI-0621, in a new webcast, aiming to capture investor and scientific attention before a key industry congress.

Cardurion is set to reveal pivotal Phase 2 data for Tovinontrine, a first-in-class drug aiming to help millions suffering from chronic heart failure.

As a deadly Bundibugyo ebolavirus outbreak grips the DRC, a $16.5M CEPI investment in Egypt's Minapharm marks a pivotal shift toward African health sovereignty.

An Argentine firm is scaling up to challenge global pharma giants, promising a more stable supply of a critical drug and a new model for trust in medicine.

Xeris Biopharma's XP-8121 aims to solve a key problem in hypothyroidism. Can this weekly injection capture a multi-billion dollar market from daily pills?